Tangen Biosciences Secures $9M Series A Funding to Advance Isothermal Nucleic Acid Testing Platform TangenDx for HIV Diagnostics

VCBeat (WeChat ID: vcbeat) learned from foreign media that on June 20, U.S. local time, medical device company Tangen Biosciences completed a $9 million Series A financing round. The proceeds from this round will be used to support the next phase of clinical testing for the company’s innovative platform, TangenDx, with the aim of bringing the related technology to market as soon as possible.

It is reported that this round of financing was led by Connecticut Innovations, with participation from VC23 and other investors. Concurrently with the completion of this financing, Tangen Biosciences expanded its management team, welcoming Dr. Keith Kardos as Interim Vice President of Clinical Affairs and Anne Cavanaugh as Chief Financial Officer.

Tangen Biosciences, established in 2013 and headquartered in Connecticut, USA, is a medical device company dedicated to the research and development of rapid nucleic acid testing technologies. Richard C. Birkmeyer serves as the Chief Executive Officer of Tangen Biosciences; an experienced executive, he joined the company in November 2018.

Tangen Biosciences’ flagship product, TangenDx, is a novel isothermal nucleic acid detection platform. As a diagnostic tool, TangenDx is designed for current and future healthcare needs, aiming to provide healthcare professionals and their patients with an easy-to-use, affordable, sensitive, portable, and real-time solution for pathogen identification.

Traditional nucleic acid testing equipment is typically confined to specialized research institutions or large hospitals, where such devices are often expensive, complex to operate, and subject to significant wear and tear. To bring nucleic acid diagnostic technology to the market, TangenDx has broken down these traditional barriers by optimizing multiple functionalities of its device. The optimized system is battery-powered, equipped with rapid and accurate molecular diagnostic technology, requires no cold-chain reagents, and can accommodate various types and volumes of research samples. It offers advantages including low cost, portability, and minimal system maintenance.

Currently, nucleic acid testing in the medical field is primarily applied to HIV detection. This method directly targets the RNA or DNA structure of the HIV virus to detect the presence of viral nucleic acids in the blood, thereby diagnosing pathogen infection. If TangenDx is successfully launched into the market, this low-cost, accessible testing system will contribute to global HIV prevention and control efforts.

Daniel Wagner, Senior Managing Director at Connecticut Innovations, stated, “We are highly optimistic about the growth prospects of TangenDx. For diagnostic technologies to advance, they must focus on market commercialization rather than remaining confined to laboratory settings. Through our collaboration, we plan to introduce TangenDx into various healthcare settings, such as physicians’ offices, pharmacies, and healthcare clinics.”

Connecticut Innovations, established in 1995 and headquartered in Connecticut, USA, is a venture capital and private equity firm dedicated to providing growth capital to companies in high-tech sectors such as energy, biotechnology, information technology, and photonics. To date, it has completed 194 investments.

Headquartered in Connecticut, USA, VC23 is a venture capital firm focused on investing in the innovative technology sector. In addition to providing financial support to companies, VC23 also offers professional management teams to help entrepreneurs manage and grow their businesses scientifically.

(Compiled by Liu Yujing)